[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_99":100},"en-item",{"_9":10,"_10":11},"kind","item",{"_12":13,"_14":15,"_16":17,"_18":19,"_20":21,"_22":23,"_24":25,"_26":27,"_28":29,"_30":31,"_32":31,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":46,"_47":-5,"_48":49,"_50":-5,"_51":-5,"_52":53,"_54":55,"_56":57,"_58":42,"_59":42,"_60":61,"_62":42,"_63":64},"id","pbhigwanl1q16plvracdiju3v","revision",2,"title","Evaxion A/S公布个性化癌症疫苗EVX-01三周年随访结果","originalTitle","6-K - Evaxion A/S (0001828253) (Filer)","summary","Evaxion A/S公布其个性化癌症疫苗EVX-01在II期试验中三周年随访显示所有患者持续临床反应，相关报告作为Form 6-K附件披露。","reason","Evaxion A/S公布其个性化癌症疫苗EVX-01在II期试验中三周年随访显示所有患者持续临床反应，可能对AI-Immunology™领域产生影响。","source",{"_12":90,"_91":92,"_9":93,"_94":42,"_95":96,"_97":98},"links",{"_87":88,"_78":89},"publishedAt","2026-10-19T10:00:07.000Z","discoveredAt","2026-10-19T10:47:19.494Z","timelineAt","category","ai-products","tags",[83,84,85,86],"stockSymbols",[82],"score",60,"selected",true,"channel","news","story",{"_73":74,"_16":75},"x","readingMode","full","author","language","body",{"_64":77,"_78":-5,"_79":80,"_81":42},"outline",[],"relatedStories",[76],"indexable","markdownAvailable","group",{"_65":66,"_45":67,"_68":69,"_70":71,"_72":71},"hasTranslation","bodyLanguage","zh","factId","fRj44cbj2FmU",{"_73":74,"_16":75},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","ca1d56a5-3da4-4a71-83a7-e2fcf18cd920","Evaxion A/S公布EVX-01三周年随访结果",{"_73":74,"_16":75},"

美国
证券交易委员会
华盛顿特区 20549

6-K表

外国私人发行人根据1934年证券交易法第13a-16或15d-16条提交的报告

2026年10月

委员会文件编号： 001-39950

Evaxion A/S
(根据其章程规定的注册人准确名称)

Neergaards Vej 5f
DK-2970 Hoersholm
丹麦
(主要执行办公室地址)

通过勾选方框表明注册人是否以20-F表或40-F表的形式提交年度报告。

20-F [ X ] 40-F [ ]

参考引用

本6-K表将被视为参考引用，纳入Evaxion A/S在S-8表（文件编号333-255064）、F-3表（文件编号333-265132）、F-1表（经修订，文件编号333-266050）、F-1表（文件编号333-276505）、F-1表（文件编号333-279153）、F-1表（文件编号333-283304）和F-3表（文件编号333- 285778）中的注册声明，包括构成此类注册声明一部分的任何招股说明书，并自本报告提交之日起成为其一部分，除非随后提交或提供的文件或报告另有规定。

新闻稿

2026年10月19日，Evaxion A/S（“公司”）是一家临床阶段的TechBio公司，专注于开发AI-Immunology™驱动的疫苗，发布了题为“Evaxion在个性化癌症疫苗EVX-01的二期试验中，三年随访时所有患者均表现出持续的临床反应”的新闻稿。本6-K表的此报告附有该新闻稿的副本作为附件99.1。

附件

附件编号		描述

99.1		Evaxion在个性化癌症疫苗EVX-01的二期试验中，三年随访时所有患者均表现出持续的临床反应

签名

根据1934年证券交易法的要求，注册人已 duly 促使本报告由受权代表签署。

		Evaxion A/S
		（注册人）


日期：2026年10月19日	由：	/s/ Helen Tayton-Martin
		Helen Tayton-Martin
		首席执行官

","original","zhKind","translation","complete","EVAX","公司与财报","行业与主题","观点与解读","其他","aihot","/items/pbhigwanl1q16plvracdiju3v","https://www.sec.gov/Archives/edgar/data/1828253/000117184326006678/0001171843-26-006678-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792627200&sig=564cbec5bb9177d7","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792627200&sig=034656c278a8477b 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792627200&sig=23dae0083a3a8d72 96w","changelogVersion","2026-10-01T08:00"]